Spruce Biosciences, Inc. (SPRB) DCF Valuation
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Spruce Biosciences, Inc. (SPRB) Bundle
Looking to assess the intrinsic value of Spruce Biosciences, Inc.? Our (SPRB) DCF Calculator integrates real-world data with comprehensive customization features, enabling you to refine projections and enhance your investment strategies.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | .0 | .0 | .0 | .0 | 10.1 | 10.1 | 10.1 | 10.1 | 10.1 | 10.1 |
Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITDA | -13.1 | -29.1 | -41.6 | -45.3 | -47.4 | 6.1 | 6.1 | 6.1 | 6.1 | 6.1 |
EBITDA, % | 100 | 100 | 100 | 100 | -469.48 | 60 | 60 | 60 | 60 | 60 |
Depreciation | .0 | .1 | .4 | .4 | .1 | 8.1 | 8.1 | 8.1 | 8.1 | 8.1 |
Depreciation, % | 100 | 100 | 100 | 100 | 0.69382 | 80.14 | 80.14 | 80.14 | 80.14 | 80.14 |
EBIT | -13.1 | -29.2 | -41.9 | -45.8 | -47.4 | 6.1 | 6.1 | 6.1 | 6.1 | 6.1 |
EBIT, % | 100 | 100 | 100 | 100 | -470.18 | 60 | 60 | 60 | 60 | 60 |
Total Cash | 3.9 | 157.2 | 89.0 | 79.1 | 96.3 | 10.1 | 10.1 | 10.1 | 10.1 | 10.1 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .0 | .0 | .0 | .0 | .0 | 8.1 | 8.1 | 8.1 | 8.1 | 8.1 |
Account Receivables, % | 100 | 100 | 100 | 100 | 0 | 80 | 80 | 80 | 80 | 80 |
Inventories | .0 | .0 | .0 | .0 | .0 | 8.1 | 8.1 | 8.1 | 8.1 | 8.1 |
Inventories, % | 100 | 100 | 100 | 100 | 0 | 80 | 80 | 80 | 80 | 80 |
Accounts Payable | 1.9 | 3.6 | 2.8 | 1.4 | 3.3 | 8.7 | 8.7 | 8.7 | 8.7 | 8.7 |
Accounts Payable, % | 100 | 100 | 100 | 100 | 33.03 | 86.61 | 86.61 | 86.61 | 86.61 | 86.61 |
Capital Expenditure | .0 | -.1 | -.1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Capital Expenditure, % | 100 | 100 | 100 | 100 | -0.0693825 | -0.0138765 | -0.0138765 | -0.0138765 | -0.0138765 | -0.0138765 |
Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITAT | -13.3 | -29.7 | -42.3 | -44.7 | -47.4 | 6.0 | 6.0 | 6.0 | 6.0 | 6.0 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -11.4 | -27.9 | -42.9 | -45.6 | -45.5 | 3.4 | 14.1 | 14.1 | 14.1 | 14.1 |
WACC, % | 14.52 | 14.52 | 14.52 | 14.47 | 14.52 | 14.51 | 14.51 | 14.51 | 14.51 | 14.51 |
PV UFCF | ||||||||||
SUM PV UFCF | 38.5 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 14 | |||||||||
Terminal Value | 115 | |||||||||
Present Terminal Value | 58 | |||||||||
Enterprise Value | 97 | |||||||||
Net Debt | -92 | |||||||||
Equity Value | 189 | |||||||||
Diluted Shares Outstanding, MM | 39 | |||||||||
Equity Value Per Share | 4.90 |
What You Will Get
- Comprehensive SPRB Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust parameters like WACC, tax rates, revenue growth, and capital expenditures.
- Dynamic Calculations: Intrinsic value and NPV are computed in real-time.
- Scenario Analysis: Explore various scenarios to assess Spruce Biosciences' future prospects.
- User-Friendly Design: Designed for experts but easy to navigate for newcomers.
Key Features
- Comprehensive SPRB Data: Pre-loaded with Spruce Biosciences' historical performance metrics and future growth forecasts.
- Customizable Parameters: Tailor revenue growth, operating margins, discount rates, tax considerations, and capital investments to your needs.
- Interactive Valuation Tool: Real-time adjustments to Net Present Value (NPV) and intrinsic value based on user-defined inputs.
- Multiple Scenario Analysis: Develop various forecasting scenarios to evaluate different valuation possibilities.
- Intuitive User Interface: Designed for ease of use, making it accessible for both industry experts and newcomers.
How It Works
- Step 1: Download the prebuilt Excel template featuring Spruce Biosciences' data.
- Step 2: Navigate through the pre-filled sheets to grasp the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly see recalculated results, including Spruce Biosciences' intrinsic value.
- Step 5: Utilize the outputs to make informed investment decisions or create reports.
Why Choose This Calculator for Spruce Biosciences, Inc. (SPRB)?
- Accuracy: Utilizes real Spruce Biosciences financials to ensure precise data.
- Flexibility: Allows users to easily test and adjust inputs as needed.
- Time-Saving: Avoid the complexities of building a financial model from the ground up.
- Professional-Grade: Crafted with the precision and usability expected at the CFO level.
- User-Friendly: Designed for ease of use, suitable for those without extensive financial modeling skills.
Who Should Use This Product?
- Investors: Accurately assess Spruce Biosciences, Inc.'s (SPRB) fair value before making investment choices.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to Spruce Biosciences, Inc. (SPRB).
- Consultants: Efficiently customize the template for valuation reports tailored to Spruce Biosciences, Inc. (SPRB) clients.
- Entrepreneurs: Acquire insights into financial modeling practices utilized by leading biotech firms.
- Educators: Employ it as a teaching resource to illustrate valuation methodologies in the biotech sector.
What the Template Contains
- Pre-Filled DCF Model: Spruce Biosciences' financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Spruce Biosciences' profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.